Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2026)

Crinetics Pharmaceuticals' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $12.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 14.63% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $49.8 million (up 1.78% YoY), while the FY2025 annual figure was $52.0 million, up 25.47% from the prior year.
• Interest & Investment Income was $12.7 million for Q1 2026 at Crinetics Pharmaceuticals, up from $11.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $14.8 million in Q1 2025 to a low of $193000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $7.3 million across 5 years, with a median of $7.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 6150.0% in 2022, then dropped 22.36% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $1.9 million in 2022, then soared by 253.05% to $6.7 million in 2023, then soared by 113.75% to $14.4 million in 2024, then slipped by 22.36% to $11.2 million in 2025, then increased by 13.52% to $12.7 million in 2026.
• The last three Interest & Investment Income figures came in at $12.7 million (Q1 2026), $11.2 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.